| INTRODUC TI ON
The clinical success of immune checkpoint blockade has brought about dramatic "breakthroughs" in oncology. Immune checkpoint inhibitors (ICIs) have emerged as the new standard treatment in many different types of malignant tumor, including malignant melanoma, [1] [2] [3] [4] [5] [6] nonsmall cell lung cancer (NSCLC), [7] [8] [9] [10] head and neck cancer, 11 renal cell carcinoma, 12 urothelial cancer, 13, 14 and Hodgkin's lymphoma. 15, 16 Immune In multivariate analysis, elevated TSH and TgAb at baseline were significantly associated with the development of TD, with odds ratio of 7.36 (95% CI, 1.66-32.7) and 26.5 (95% CI, 8.18-85.8),
respectively. Association between TD and elevated antithyroid peroxidase Abs at baseline was not significant. These results suggest that patients with pre-existing TgAb and elevated TSH at baseline are at high risk of TD.
K E Y W O R D S
antithyroglobulin antibody, antithyroid peroxidase antibody, immune-related adverse event, nivolumab, thyroid dysfunction the skin, gastrointestinal tract, and endocrine organs. The majority (~80%) of these irAEs resolve within a median of 5 weeks from the onset by the use of immune-modulating medication. 17 Endocrine irAEs, including thyroid dysfunction (TD), adrenal insufficiency, hypophysitis, and type 1 diabetes, have been reported. 18 Of these endocrine irAEs, TD, including hypothyroidism, thyrotoxicosis, and thyroiditis, is one of the most frequent irAEs, observed in more than 10% of patients treated with ICIs. Although most cases of TD are mild, high-grade thyrotoxicosis and hypothyroidism are also reported at low frequency (<1%) in clinical trials. 4, 6 Even though TD is a common irAE, the etiology and precise clinical course of TD have not been sufficiently identified. Here, to identify the risk factors and clinical course of ICI-induced TD, we retrospectively examined thyroid function and antithyroid Abs among patients treated with nivolumab. 
| MATERIAL S AND ME THODS

| Patients and study design
| Statistical analysis
All patients were classified into two cohorts, based on the presence of thyroid autoimmunity at baseline. Differences between covariates in the two cohorts were compared using the Mann-Whitney U test or
Fisher's exact test. Possible explanatory factors for the development of TD were analyzed using a multivariate logistic regression model.
A multivariate model initially included age (<65 years, ≥65 years), sex (male, female), ECOG PS (0-1, 2-3), THS (<5μIU/mL, ≥5μIU/mL), TPOAb (presence, absence), TgAb (presence, absence), and thyroid autoimmunity (presence, absence). A stepwise model selection was carried out with P value thresholds of .05 for inclusion and .10 for exclusion. In this model, candidate variables were tested with stepwise forward selection method. Cumulative incidence of TD was estimated using the Kaplan-Meier method. A difference in cumulative incidence between patients with and without thyroid autoimmunity before nivolumab treatment was assessed with the log-rank test, and hazard ratio (HR) and 95% confidence interval (CI) were estimated with a Cox proportion hazard model. In patients who developed TD, association between time-to-onset of TD and titer of TgAb at baseline was examined using the Mann-Whitney test. All statistical analyses were undertaken using spss 23.0 (IBM, Armonk, NY, USA).
| RE SULTS
| Patient characteristics
A total of 256 patients with malignant solid tumors were treated with nivolumab. Sixty-seven patients were excluded from this study 
| Onset and timing of TD
At the time of data cut-off (31 August 2016), median follow-up time was 272 days (range, 100-2529 days). Twenty-three of 168 patients (14%) developed TD, including thyrotoxicosis and hypothyroidism (Table S1 ).
There were no significant differences between patients who developed TD (N = 23) and those who did not (N = 145) in terms of patient characteristics such as age, sex, and ECOG PS, except for the evidence of thyroid autoimmunity at baseline (P < .001, Fisher's exact test; Table 2 ). Presence of TgAb alone (≥28 IU/mL) 12 (7) 12 ( TSH ≥ ULN, <10 μIU/mL 11 (7) 2 (6) 9 (7) NSCLC, nonsmall cell lung cancer; PS, performance status; TgAb, antithyroglobulin Ab; TPOAb, antithyroid peroxidase Ab; TSH, thyroid-stimulating hormone.
Thyrotoxicosis and hypothyroidism occurred in 20 (12%) and 17 patients (10%), respectively (Table S1) 
| Association between development of TD and thyroid autoimmunity before nivolumab
The incidence of TD in patients with thyroid autoimmunity at baseline was 40% (N = 14/35), whereas it was 7% (N = 9/133) in The cumulative incidence of thyrotoxicosis and hypothyroidism using the Kaplan-Meier method was overwhelmingly higher in patients with thyroid autoimmunity than in patients without ( Figure 2 ).
The HR in thyrotoxicosis was 11.3 (95% CI, 4.35-29.6; P < .01), and the HR in hypothyroidism was 11.0 (95% CI, 3.89-31.4; P < 0.01). In all patients who developed thyrotoxicosis (N = 20), incidence rates within 3 months and 6 months were 86% and 100% in patients with thyroid autoimmunity and 67% and 100% in those without. In all patients who developed hypothyroidism (N = 17), incidence rates within 3 and 6 months were 58% and 100% in patients with thyroid autoimmunity and 40% and 80% in those without. Additionally, Figure 3 shows the association of baseline titer of TgAb and time- All TD events except 1 developed within 6 months from the initiation of nivolumab. The cumulative incidence reached a plateau within 9 months, and no events occurred thereafter (Figure 2 ). F I G U R E 2 Cumulative incidence of thyrotoxicosis and hypothyroidism among patients with advanced solid tumors treated with nivolumab. Broken line, patients with thyroid autoimmunity; solid line, those without. Patients who were lost to follow-up and those still alive at the cut-off date were censored. Termination of nivolumab treatment was not a censored event. Incidence rate indicates the rate of cumulative event at each time point among all patients who developed thyrotoxicosis and hypothyroidism
TA B L E 3 Logistic regression analysis to identify risk factors for the development of thyroid dysfunction among patients with advanced solid tumors treated with nivolumab
| Association between development of TD and survival
Median overall survival of all patients was 1.41 years (95% CI, 0.71-2.10; Figure S1A ). Overall survival in patients with TD was numerically longer than that without TD, albeit without statistical significance (HR 0.52; 95% CI, 0.25-1.11; P = .09) ( Figure S1B ).
| D ISCUSS I ON
Our study showed that TD induced by ICIs was common, occurred early, and had unique kinetics with transient thyrotoxicosis followed by hypothyroidism. The signs and symptoms of TD were mild, various, and non-specific. As patients with hypothyroidism often require hormone replacement therapy for a long period and rarely develop thyroid crisis, the early and precise diagnosis and appropriate management of TD are important for oncologists in practice.
This study can be considered as one utilizing real-world data,
given that our study included a large number of patients with NSCLC, malignant melanoma, and other types of cancer who were treated with nivolumab in investigational trials and clinical practice.
In fact, the frequency of hypothyroidism induced by nivolumab in our study was comparable to results from clinical trials (9%-10.8%) 24 and post-marketing surveillance (11.3%). 25 Recently, an irAE management guide has been published, the American Society of Clinical Oncology Clinical Practice Guideline. 26 However, baseline risk of development of TD is not included in this guidance. We identified the increased level of TSH and the presence of TgAb at baseline as risk factors for TD induced by nivolumab treatment. In addition, the Kaplan-Meier curve indicated that almost all patients developed TD within 6 months from the initiation of nivolumab treatment and that the cumulative incidence achieved a plateau within 9 months. These findings can help to predict who and when TD is induced by nivolumab.
To date, several investigational trials and case series presented In the current study, the incidence of TD was significantly higher in patients with thyroid autoimmunity than in those without. These findings consistently suggest that thyroid Abs play essential roles in the development of TD induced by ICIs.
However, whether TgAb and TPOAb have the same impact on the development of TD is not well known. Our study showed that the presence of TgAb before nivolumab was associated with a large and significant HR of TD compared to that of TPOAb (Table 3) . Different results between ours and other studies might be based on the number of We consider that Tg-specific immunity plays a predominant role in destructive thyroiditis induced by nivolumab compared with TPO-specific immunity, whereas both Tg-and TPO-specific CD8-positive T cells are involved in the thyroid destruction of Hashimoto's thyroiditis. 29 Transient thyrotoxicosis followed by permanent hypothyroidism, as observed in our study, was previously reported. 30 This unique pattern is considered to be caused by acute inflammation and subsequent destruction of the thyroid gland by thyroid autoimmunity.
Indeed, all patients recovered from transient thyrotoxicosis, with a median duration of 32.5 days, suggesting the development of destructive thyroiditis. Moreover, patients who developed thyrotoxicosis only and did not develop hypothyroidism were also observed in our study. Interestingly, 5 of 6 patients received systemic steroid therapy during the thyrotoxicosis period for various reasons.
Although the dose and duration of systemic steroid therapy varied, use of an immune suppressive agent in the acute inflammation period might avoid permanent destruction of the thyroid gland. Steroid therapy at the onset of thyrotoxicosis could prevent permanent hypothyroidism, but further investigation is warranted.
Several studies have suggested that development of irAEs is associated with better clinical response and outcome. [31] [32] [33] [34] [35] Our study also showed that the survival of those who experienced TD tended to be better than that of those who did not, especially patients with malignant melanoma ( Figure S1C ). These findings imply the same underlying mechanism enhancing the immune response against tumor cells and self-organs.
Our study has several limitations. First, although we evaluated thyroid function at baseline and during nivolumab treatment almost every 2 months, potential measurement bias was present in the different intervals for onset time and duration between events. Second, most patients were evaluated prospectively for thyroid function and antithyroid Abs titer in clinical practice and sponsor-initiated investigational trials. Moreover, missing cases were measured retrospectively from preserved serum samples.
The decision to initiate treatment for thyrotoxicosis and hypothyroidism was made by the attending physicians depending on the clinical presentation.
In conclusion, our large cohort study revealed that TgAb was associated with the development of nivolumab-induced TD. This large cohort study in which all subjects could be assessed for thyroid function and antithyroid Abs before and during nivolumab treatment has clearly depicted the clinical course of TD using real-world data.
These findings suggest that the optimal management of TD based on risk factors can be clinically useful.
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